BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June

Day

• 2
• 3
• 4
• 5
• 6
• 7
• 9
• 10
• 11
• 12
• 13
• 14
• 17
• 18
• 19
• 20
• 21
• 24
• 25
• 26
• 27
• 28

• 

  Psychedelics

  Psychedelics Space Regroups as RFK Jr. Signals Support

  After the rejection of Lykos Therapeutics’ MDMA-based PTSD treatment tempered excitement for psychedelic therapeutics, a recent approval and positive data are generating new momentum, which experts expect to continue throughout 2025 and 2026.

  February 17, 2025

   · 

  5 min read

   · 

  Heather McKenzie
• 

  Immunology and Inflammation

  I&I Investment Ramps Up With Novel Targets and Boundless Opportunity

  Biopharma doubles down on immunology and inflammation as companies target new pathways and seek to improve on current options in inflammatory bowel disease, atopic dermatitis, myasthenia gravis and more.

  February 17, 2025

   · 

  5 min read

   · 

  Kate Goodwin
• 

  Cancer

  Ono’s FDA Rare Cancer Approval Sets Up Face Off With Daiichi Sankyo

  Ono picked up Romvimza—previously known by its active ingredient vimseltinib—from its $2.4 billion acquisition of Deciphera Pharmaceuticals in April 2024.

  February 17, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  FDA

  ‘No Job Security’ at FDA as Trump Team Seeks to Dismantle Workforce: Updated

  The hammer came down on an unspecified number of FDA employees this weekend, days after Robert F. Kennedy Jr. was confirmed as HHS Secretary.

  February 17, 2025

   · 

  6 min read

   · 

  Heather McKenzie
• 

  Drug Development

  Healthcare at a Crossroads: Maintaining Good Science in Uncertain Times
  

  Continuing our SCOPE 2025 coverage, Rohit Nambisan, CEO at Lokavant addresses not only current challenges, but the life sciences industry’s responsibility to maintain scientific integrity.

  February 17, 2025

   · 

  1 min read

   · 

  Lori Ellis
• 

  Approvals

  Sanofi Challenges Novo With First FDA Nod for NovoLog Biosimilar

  Merilog’s approval comes as the insulin space has over the past year suffered several setbacks, including strong calls for price caps and, potentially, the rise of the mammoth GLP-1 market.

  February 17, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Vaccines

  FDA Issues Back-to-Back Vaccine Approvals as RFK Jr. Takes HHS Seat

  The approvals come as Robert F. Kennedy Jr.—who has been critical of vaccines—takes leadership of the Department of Health and Human Services.

  February 17, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Opinion

  Companies Take Multiple Tacks Against Myotonic Dystrophy Type 1

  With its recent data drop for an oligonucleotide candidate, Dyne Therapeutics signals it may become a frontrunner in this disease space alongside Avidity Biosciences, Lupin and AMO Pharma.

  February 17, 2025

   · 

  4 min read

   · 

  Jia Jie Chen
• Press Releases

  Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

  February 17, 2025

   · 

  2 min read
• Press Releases

  Cellistic Launches Allo Chassis™: Ready-to-use, immune-cloaked iPSC Cell Lines facilitating cost-effective cell therapy development

  February 17, 2025

   · 

  2 min read